Key Takeaways Revvity joins forces with Eli Lilly to offer TuneLab models via the Signals Xynthetica platform.The deal tackles AI drug discovery bottlenecks using federated learning and secure knowledge sharing.RVTY will co-fund select biotechs, lowering entry barriers and supporting adoption of the Signals ecosystem.Revvity, Inc. (RVTY) recently announced a collaboration with Eli Lilly and Company to make Eli Lilly’s TuneLab predictive models available through the Revvity Signals platform. The partnership ...

Core Viewpoint - Revvity, Inc. (RVTY) is expected to report its first-quarter 2025 results on April 28, with a consensus estimate for revenues at $662.2 million, reflecting a 1.9% increase year-over-year, while earnings per share (EPS) is projected at 96 cents, indicating a 2% decline year-over-year [1][2]. Q1 Estimates - The Zacks Consensus Estimate for revenues is $662.2 million, up 1.9% from the prior-year quarter [1] - The consensus mark for earnings is 96 cents per share, indicating a deterioration of 2% year-over-year [1] - Organic top-line growth is expected to be 3-5% in Q1, with 19% of full-year adjusted EPS guidance of $4.90-$5.00 anticipated in this quarter [2] Diagnostics Segment - The Diagnostics segment sales improved 6% organically in the fourth quarter, with strong performance expected to continue in Q1, driven by growth in Immunodiagnostics and Reproductive Health [3] - Immunodiagnostics is projected to grow in high-single digits, supported by strong commercial execution [3] - The estimated revenue for the Diagnostics segment is $324.8 million, down 6.4% year-over-year [6] Life Sciences Segment - The Life Sciences business improved 5% organically in the last reported quarter, primarily driven by recovery in pharma/biotech customer activity [7] - The estimated revenue for the Life Sciences segment is $338 million, up 11.6% year-over-year [8] - New offerings, Signals Clinical and Signals Synergy, are likely to drive adoption of Signals software during Q1 [7] Other Factors to Consider - Revvity announced an expansion of its work with Genomics England to advance genomic initiatives, which may boost newborn screening [9] - The launch of the TotalSeq Phenocyte single-cell protein profiling solution in collaboration with Scale Biosciences may have contributed additional revenues for the Life Sciences segment [10] - The company generates a portion of its sales from China, which is a crucial growth factor for its business in Asia [11] Earnings Beat Likely - The model predicts an earnings beat for Revvity, with an Earnings ESP of +0.52% [12]